Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
This study has been completed.
Seoul National University Hospital
Clinical Research Center for Solid Tumor, Korea
Information provided by (Responsible Party):
Dae Seog Heo, Seoul National University Hospital
First received: February 17, 2008
Last updated: December 3, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||August 2013|
|Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Lee KW, Koh Y, Kim SB, Shin SW, Kang JH, Wu HG, Sung MW, Keam B, Kim DW, Kim TM, Kim KH, Kwon TK, Hah JH, Kim IA, Ahn SH, Yoon DH, Lee SW, Kim SY, Nam SY, Jung KY, Baek SK, Hong SH, Lee SH, Heo DS. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist. 2015 Oct;20(10):1119-20. doi: 10.1634/theoncologist.2015-0208.